Results 61 to 70 of about 141,477 (341)
JAMA Internal Medicine, 2020 Importance Guidelines currently recommend ticagrelor over clopidogrel for patients with acute coronary syndrome (ACS) based on randomized clinical trial data in which ticagrelor reduced major adverse coronary events (MACE) vs clopidogrel but increased ...
R. Turgeon +6 more
semanticscholar +1 more source
Clopidogrel in Orthopaedic patients: a review of current practice in Scotland
Thrombosis Journal, 2007 Background Clopidogrel bisulfate is an antiplatelet agent used to prevent ischaemic events in patients with vascular disease. Current guidelines recommend withholding clopidogrel for 7 days pre-operatively.
Bramley Diane +2 more
doaj +1 more source
Priority setting for research in health care: An application of value of information analysis to glycoprotein IIb/IIIa antagonists in non-ST elevation acute coronary syndrome [PDF]
, 2006 The purpose of this study is to explain the rationale for the value of information approach to priority setting for research and to describe the methods intuitively for those familiar with basic decision analytical modeling.
Bojke, L. +4 more
core +1 more source
Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome
Circulation, 2020 Supplemental Digital Content is available in the text. Background: The comparative efficacy and safety of ticagrelor versus clopidogrel in older patients with myocardial infarction (MI) has received limited study.
K. Szummer +8 more
semanticscholar +1 more source
BMC Cardiovascular Disorders, 2022 Backgrounds Remarkable interindividual variability in clopidogrel response is observed, genetic polymorphisms in P2RY12 and its signal pathway is supposed to affect clopidogrel response in CHD patients.
Yan-Jiao Zhang +6 more
doaj +1 more source
Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke:Pooled analysis of randomized trials [PDF]
, 2015 Background and Purpose: Lacunar stroke accounts for ≈25% of ischemic stroke, but optimal antiplatelet regimen to prevent stroke recurrence remains unclear.
Benavente, Oscar R. +5 more
core +1 more source
Enantiopure Chiral Crystals: A Powerful Tool for Absolute Asymmetric Synthesis
Asian Journal of Organic Chemistry, EarlyView.This review covers absolute asymmetric syntheses, which allow the preparation of enantiomerically enriched chiral compounds from achiral precursors. By exploiting the crystallization of certain compounds as a conglomerate, enantiopure chiral crystals are spontaneously obtained.
Jiacheng Li, Valérie Alezra
wiley +1 more source
Clopidogrel: A multifaceted affair [PDF]
The Journal of Clinical Pharmacology, 2014 AbstractClopidogrel has been the therapy of choice, combined with aspirin, against platelet aggregation in patients at risk of suffering a vascular thrombotic event. Not all patients respond equally to clopidogrel, an observation that has led to searching for a test that, in the clinical setting, could predict patients' “resistance” to therapy.
Antonio Tugores +1 more
openaire +4 more sources
Genetic determinants of response to clopidogrel and cardiovascular events.
New England Journal of Medicine, 2009 BACKGROUND Pharmacogenetic determinants of the response of patients to clopidogrel contribute to variability in the biologic antiplatelet activity of the drug.
T. Simon +10 more
semanticscholar +1 more source
Animal Models and Experimental Medicine, EarlyView.This study evaluates the role of elastin in vascular response 28 days after balloon angioplasty using uncoated and paclitaxel‐coated balloons in a healthy porcine model. The results show higher elastin content in external femoral arteries, which is inversely correlated with vascular injury, inflammation, smooth muscle cell loss, proteoglycan and fibrin
María Gracia de Garnica García +7 more
wiley +1 more source